SB 1263 revises Texas’s prescription drug safe disposal pilot program to shift administration from the Texas State Board of Pharmacy to the Health and Human Services Commission and the Department of State Health Services. The bill is aimed at increasing the number of collection receptacles at pharmacies where the public can drop off unused, unwanted, or expired prescription drugs, including controlled substances, for safe disposal. It also updates definitions and program procedures to reflect the new administering agencies and current federal controlled-substance disposal rules.
The bill expands and clarifies how pharmacies may participate. Eligible pharmacies must be able to register with the federal Drug Enforcement Administration as authorized drug collection sites and meet applicable federal requirements. The department must prioritize pharmacies that do not already collect unused drugs or that are located in rural or underserved areas, and multi-location pharmacies may apply for all locations through one application. The bill also allows controlled substances, noncontrolled prescription drugs, and over-the-counter drugs to be collected together in the same receptacle.
SB 1263 changes the state’s financial support structure for the pilot program. It requires the department to assist participating pharmacies by paying the costs of maintaining collection receptacles and destroying the collected drugs, and it authorizes use of the opioid abatement account, along with gifts, grants, and donations, to fund the program. The bill also directs the department to contract with a DEA-registered reverse distributor for installation and incineration services, and it requires educational outreach materials in English, Spanish, and other languages as appropriate.
The bill’s impact on state law is to modernize Chapter 442A of the Health and Safety Code, transfer responsibilities to state health agencies, remove obsolete provisions, and strengthen the framework for a statewide disposal pilot. It also requires biennial reporting to the governor and legislature on receptacle distribution, amounts collected, program costs, participating pharmacies, and outreach efforts, along with a recommendation on whether the pilot should continue, expand, or become permanent.
The overall sentiment appears favorable, with strong Senate support reflected in passage on third reading by 28-3, though one recorded vote was narrower at 17-14. The main points of contention appear to have been the scope of state involvement, the use of opioid abatement funds, and the shift away from the Board of Pharmacy to HHSC/DSHS administration. The bill’s emphasis on rural and underserved access, public safety, and drug misuse prevention suggests broad policy support, but the recorded opposition indicates some disagreement over program structure and funding.
SB 1263 amends Chapter 442A of the Health and Safety Code to reassign administration of the prescription drug safe disposal pilot program from the Texas State Board of Pharmacy to the Health and Human Services Commission and the Department of State Health Services. It expands pharmacy participation rules, authorizes co-mingled collection of controlled substances, noncontrolled prescription drugs, and over-the-counter drugs, and requires the state to fund receptacle maintenance and disposal costs using the opioid abatement account and other donations. The bill also repeals outdated provisions and requires ongoing reporting and outreach, affecting pharmacies, state health agencies, reverse distributors, and the public seeking safe disposal options.
The bill appears to have generally positive support as a public health and drug safety measure, with the Senate approving it by a wide margin on key votes. The discussion implied by the bill structure emphasizes expanding access, especially in rural and underserved areas, and improving safe disposal infrastructure. At the same time, the presence of a small but notable number of مخالف votes suggests some concern about administrative changes, state spending, or the use of opioid settlement funds.
The main areas of contention are likely the transfer of program authority from the Board of Pharmacy to HHSC/DSHS, the use of opioid abatement funds to support the pilot, and the extent of state reimbursement for pharmacy participation and disposal costs. Some opposition may also relate to whether the program should be expanded through a state-funded pilot versus left to existing pharmacy or federal disposal systems. The bill’s prioritization of pharmacies in rural or underserved areas and its requirement that pharmacies meet DEA collection-site standards appear to be less controversial than the funding and governance changes.